Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas
- PMID: 12960115
Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas
Abstract
Purpose: The aim of this report was to indicate both the advantages and disadvantages of local cell transfer therapy using ex vivo expanded autologous tumor-specific T lymphocytes (ATTLs) for recurrent cases of malignant gliomas.
Experimental design: Subjects are 10 cases of malignant gliomas consisting of 7 cases of glioblastoma multiforme, 2 cases of anaplastic astrocytoma, and 1 case of anaplastic oligoastrocytoma. All cases were recurrences. ATTLs were induced by coculturing peripheral blood mononuclear cells with autologous tumor cells in medium containing interleukin-1, -2, -4, and -6 and administered into the local tumor site in total numbers of 3-247 x 10(7) cells. As end points, tumor response and survival time were analyzed observing clinical state.
Results: Five cases responded to this therapy (namely, one case showed complete remission, and four cases had a partial response). There were three cases of no change, and two cases of progressive disease. The overall tumor response rate was 50%. No complications were noticed, except for two cases of minor local hemorrhage and eight cases of temporary fever. Nine cases died of further tumor progression, and one case died of aspiration pneumonia, and the cause-specific survival analysis indicates that the median survival time was 5 months from the initial ATTL injection.
Conclusions: The results suggest that local administration of ATTLs is effective in recurrent malignant gliomas in that it demonstrated a high benefit:risk ratio with minor side effects. Although its antitumor effect may be temporary in some advanced cases, it is highly possible that the tumor could be stabilized when conditions are optimal.
Similar articles
-
T cell adoptive immunotherapy of newly diagnosed gliomas.Clin Cancer Res. 2000 Jun;6(6):2209-18. Clin Cancer Res. 2000. PMID: 10873070 Clinical Trial.
-
Autologous natural killer cell therapy for human recurrent malignant glioma.Anticancer Res. 2004 May-Jun;24(3b):1861-71. Anticancer Res. 2004. PMID: 15274367 Clinical Trial.
-
Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.Cancer Res. 2004 Jul 15;64(14):4973-9. doi: 10.1158/0008-5472.CAN-03-3505. Cancer Res. 2004. PMID: 15256471 Clinical Trial.
-
Biology and treatment of malignant glioma.Semin Oncol. 2000 Jun;27(3 Suppl 6):1-10. Semin Oncol. 2000. PMID: 10866344 Review.
-
Adoptive immunotherapy of CNS malignancies.Cancer Chemother Biol Response Modif. 2001;19:327-38. Cancer Chemother Biol Response Modif. 2001. PMID: 11686021 Review.
Cited by
-
Vaccine strategies for glioblastoma: progress and future directions.Immunotherapy. 2013 Feb;5(2):155-67. doi: 10.2217/imt.12.155. Immunotherapy. 2013. PMID: 23413907 Free PMC article. Review.
-
Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy.Br J Cancer. 2007 Apr 23;96(8):1293-301. doi: 10.1038/sj.bjc.6603696. Epub 2007 Mar 20. Br J Cancer. 2007. PMID: 17375044 Free PMC article.
-
Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of targeted therapies and immunotherapies in the management of progressive glioblastoma.J Neurooncol. 2022 Jun;158(2):265-321. doi: 10.1007/s11060-021-03876-7. Epub 2021 Oct 25. J Neurooncol. 2022. PMID: 34694567 Free PMC article.
-
Current and future strategies for treatment of glioma.Neurosurg Rev. 2017 Jan;40(1):1-14. doi: 10.1007/s10143-016-0709-8. Epub 2016 Apr 16. Neurosurg Rev. 2017. PMID: 27085859 Review.
-
HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.Clin Cancer Res. 2010 Jan 15;16(2):474-85. doi: 10.1158/1078-0432.CCR-09-1322. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068073 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Research Materials